290 related articles for article (PubMed ID: 18330030)
1. [Hemophilia--present and past].
Terada H
Nihon Rinsho; 2008 Mar; 66(3):591-9. PubMed ID: 18330030
[TBL] [Abstract][Full Text] [Related]
2. Treatment of patients with factor VIII and factor IX inhibitors with special focus on the use of recombinant factor VIIa.
Hedner U
Thromb Haemost; 1999 Aug; 82(2):531-9. PubMed ID: 10605747
[No Abstract] [Full Text] [Related]
3. Hemophilia.
Kashyap R; Choudhry VP
Indian Pediatr; 2000 Jan; 37(1):45-53. PubMed ID: 10745388
[No Abstract] [Full Text] [Related]
4. Gene therapy for hemophilia A.
Gan SU; Calne RY
Discov Med; 2006 Oct; 6(35):198-202. PubMed ID: 17234142
[TBL] [Abstract][Full Text] [Related]
5. Pioneering therapeutic proteins in hemophilia care through innovative technologies.
Pabinger-Fasching I; Négrier C
Thromb Res; 2016 May; 141 Suppl 3():S1. PubMed ID: 27288062
[No Abstract] [Full Text] [Related]
6. Inhibitor antibodies to factor VIII and factor IX: management.
Lusher JM
Semin Thromb Hemost; 2000; 26(2):179-88. PubMed ID: 10919411
[TBL] [Abstract][Full Text] [Related]
7. Advances in the care and treatment of children with hemophilia.
Manco-Johnson MJ
Adv Pediatr; 2010; 57(1):287-94. PubMed ID: 21056743
[No Abstract] [Full Text] [Related]
8. Back to the future: a recent history of haemophilia treatment.
Mannucci PM
Haemophilia; 2008 Jul; 14 Suppl 3():10-8. PubMed ID: 18510516
[TBL] [Abstract][Full Text] [Related]
9. Successful immune tolerance induction with high-dose coagulation factor VIII and intravenous immunoglobulins in a patient with congenital hemophilia and high-titer inhibitor of coagulation factor VIII despite unfavorable prognosis for the therapy.
Kubisz P; Plamenová I; Hollý P; Stasko J
Med Sci Monit; 2009 Jun; 15(6):CS105-11. PubMed ID: 19488019
[TBL] [Abstract][Full Text] [Related]
10. Evidence-based use of recombinant FVIIa (NovoSeven, NiaStase) for the treatment of hemophilia with inhibitors in children and adolescents.
Goldstein B; Geldziler B; Bjerre J; Seremetis S
Transfus Apher Sci; 2008 Feb; 38(1):25-32. PubMed ID: 18267372
[TBL] [Abstract][Full Text] [Related]
11. Toward optimal therapy for inhibitors in hemophilia.
Kempton CL; Meeks SL
Blood; 2014 Nov; 124(23):3365-72. PubMed ID: 25428222
[TBL] [Abstract][Full Text] [Related]
12. [Treatment of hemophilia].
Straub PW
Dtsch Med Wochenschr; 1969 Sep; 94(37):1885-7. PubMed ID: 5356323
[No Abstract] [Full Text] [Related]
13. Recombinant clotting factors in the treatment of hemophilia.
Lee C
Thromb Haemost; 1999 Aug; 82(2):516-24. PubMed ID: 10605745
[No Abstract] [Full Text] [Related]
14. Management of the haemophiliac factor.
Coutts AM
Cent Afr J Med; 1997 Sep; 43(9):277-8. PubMed ID: 9509651
[No Abstract] [Full Text] [Related]
15. Preclinical and clinical progress in hemophilia gene therapy.
Mátrai J; Chuah MK; VandenDriessche T
Curr Opin Hematol; 2010 Sep; 17(5):387-92. PubMed ID: 20657281
[TBL] [Abstract][Full Text] [Related]
16. Current status of hemophilia patients and recombinant coagulation factor concentrates in Japan.
Fukutake K
Semin Thromb Hemost; 2000; 26(1):29-32. PubMed ID: 10805278
[TBL] [Abstract][Full Text] [Related]
17. [Recombinant activated Factor VII (Novoseven Novo Nordisk) for hemostasis in acquired Factor VIII-inhibitor hemophilia].
Meili EO; Dazzi H; von Felten A
Schweiz Med Wochenschr; 1995 Mar; 125(9):405-11. PubMed ID: 7892567
[TBL] [Abstract][Full Text] [Related]
18. Management of hemophilia patients with inhibitors.
Hedner U; Glazer S
Hematol Oncol Clin North Am; 1992 Oct; 6(5):1035-46. PubMed ID: 1400071
[TBL] [Abstract][Full Text] [Related]
19. Gene therapy for hemophilia: clinical trials and technical tribulations.
Viiala NO; Larsen SR; Rasko JE
Semin Thromb Hemost; 2009 Feb; 35(1):81-92. PubMed ID: 19308896
[TBL] [Abstract][Full Text] [Related]
20. Hemophilia. Strategies for the treatment of inhibitor patients.
Ingerslev J
Haematologica; 2000 Oct; 85(10 Suppl):15-20. PubMed ID: 11187863
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
